Damora Therapeutics (DMRA)
Advances mutCALR-directed candidates for essential thrombocythemia and myelofibrosis.
Something off on this page? Send us feedback.
Develops mutCALR-targeted candidates for essential thrombocythemia and myelofibrosis. Its pre-commercial portfolio includes DMR-001, DMR-002, and DMR-003.
Development centers on mutCALR-directed therapies for myeloproliferative neoplasms, especially essential thrombocythemia and myelofibrosis. The pre-commercial pipeline includes DMR-001, a monoclonal antibody targeting Type 1 and Type 2 mutCALR; DMR-002, an undisclosed follow-on candidate; and DMR-003, a mutCALR x CD3 bispecific T-cell engager.
Clinical-development activity is concentrated on the acquired Damora portfolio after the former Galecto company's strategic reset. No candidate has been described as approved or revenue-generating. The company reports one operating and reportable segment and operates primarily in Denmark and North America. Progress depends on regulatory submissions, clinical studies, and the Paragon development and licensing arrangements.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 30, 2026 | Wedbush | Reiterate | Outperform | $35 | $40 |
| Jul 26, 2026 | Jefferies | Initiate | Buy | $50 | |
| Jun 11, 2026 | H.C. Wainwright | Target | $45 | ||
| May 28, 2026 | Wedbush | Target | $35 | ||
| Apr 23, 2026 | RBC Capital | Target | $40 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $540.5M · Total debt $0 · Total assets $543.6M · Shareholders' equity $516.1M
- Revenue
- $0
- Operating income
- −$35.0M
- Net income
- −$31.2M
No dividends on record.
| Institutions64 holders · as of Mar 31, 2026 | 90.97% | 56.00M shares | |
| Insiders2 holders · as of Jul 7, 2026 | 0.82% | 502.3K shares | |
| Otherremainder | 8.21% | 5.05M shares |
61.55M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
FMR LLCInstitution | 14.70% | 9.05M | 13Fas of Mar 31, 2026 |
Fairmount Funds Management LLCInstitution | 14.16% | 8.71M | 13Fas of Mar 31, 2026 |
Avoro Capital Advisors LLCInstitution | 6.15% | 3.78M | 13Fas of Mar 31, 2026 |
VR Adviser, LLCInstitution | 5.85% | 3.60M | 13Fas of Mar 31, 2026 |
FCPM Iii Services B.V.Institution | 3.97% | 2.44M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 6, 2026 | Garrett Winslow | officer: General Counsel | −245 | $29.98 |
- Incyte
Direct mutCALR antibody rival in ET and MF
- Johnson & Johnson
Direct mutCALR×CD3 bispecific rival in ET and MF
- GSK (ADR)
Approved MF therapy focused on patients with anemia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Damora Therapeutics | $28.22 | +0.28% | $1.73B | — | — | — | — |
| Incyte | $128.82 | +3.05% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Johnson & Johnson | $275.01 | −0.08% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| GSK (ADR) | $50.55 | +0.25% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Median | 16.4 | 23.1 | 4.5 | +6.6% |